C2N Diagnostics Expands St. Louis Headquarters Amid Alzheimer's Disease Diagnostic Advancements

C2N Diagnostics, a specialty diagnostics company, is expanding its St. Louis headquarters to meet global demand for Alzheimer's disease answers. The company will relocate its headquarters and expand its lab operation to 4140 Forest Park Ave. at Catalyst, Powered by WashU, in the Cortex Innovation District. C2N will occupy 82,451 new square feet, tripling its operations in St. Louis. The expansion is driven by the company's early achievements and its highly accurate PrecivityAD2™ blood test for Alzheimer's disease.

C2N Diagnostics, a specialty diagnostics company, has announced plans to relocate and expand its St. Louis headquarters to meet growing global demand for Alzheimer's disease diagnostics. The company will move to 4140 Forest Park Ave. at Catalyst, Powered by WashU, in the Cortex Innovation District, where it will occupy 82,451 new square feet, effectively tripling its operations in the city.

The expansion is driven by C2N's early achievements, particularly its highly accurate PrecivityAD2™ blood test for Alzheimer's disease. The test has demonstrated significant promise in early detection and monitoring of the disease, contributing to the company's rapid growth. By increasing its operational capacity, C2N aims to enhance its ability to serve a broader patient population and meet the increasing demand for Alzheimer's disease diagnostics globally.

The relocation and expansion come at a critical time as Biogen (NASDAQ: BIIB) and Eisai have recently received FDA approval for LEQEMBI IQLIK, a subcutaneous autoinjector for maintenance treatment of early Alzheimer's disease. This approval represents a significant advancement in Alzheimer's disease management, offering an at-home alternative to IV infusions and improving treatment accessibility and adherence [1].

C2N's expansion aligns with the broader trend of increasing investment in Alzheimer's disease diagnostics and treatment. The global Alzheimer's disease diagnostics market is expected to grow at a CAGR of 8.2% during the forecast period from 2023 to 2030, driven by factors such as the increasing prevalence of the disease, advancements in diagnostic technologies, and rising awareness among patients and healthcare providers [2].

By establishing a larger presence in St. Louis, C2N aims to strengthen its position in the Alzheimer's disease diagnostics market and contribute to the development of more effective treatments for the disease. The company's PrecivityAD2™ test has the potential to play a significant role in early detection and monitoring of Alzheimer's disease, helping to improve patient outcomes and reduce the burden of the disease on healthcare systems.

References:
[1] https://www.stocktitan.net/news/BIIB/fda-approves-leqembi-iqliktm-lecanemab-irmb-subcutaneous-injection-r9k723nqvbc4.html
[2] https://www.marketwatch.com/press-release/alzheimers-disease-diagnostics-market-2023-2030-global-industry-analysis-size-share-growth-trends-forecast-2023-2030-2023-09-02